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Background: Invasive lobular carcinoma (ILC) comprises 5–16% of all breast cancers, with its
incidence gradually increasing. ILC has a disproportionately higher incidence of spread to the
gastrointestinal (GI) system.
Methods: This study is a retrospective chart review of all cases of ILC with gastrointestinal
metastases seen at a university afﬁliated tertiary cancer institute between 2005 and 2010,
examining demographic, epidemiological, medical, and treatment factors that may have an
association with the risk of GI metastases.
Results: 343 consecutive cases of lobular breast cancer were reviewed, and 21(6%) were found
to have GI metastases. The mean age at initial diagnosis of primary tumor was 63 years. Stages
at presentation of the breast primary were: Stages 1/2%=73% and stages 3/4=27%. Receptor
status of the primary breast cancer was as follows: HER2+=5%, PR+=76%, ER+=90%. The
mean age at time of diagnosis of metastatic disease was 67 years. The main presenting
symptoms of GI metastatic disease were: incidental ﬁnding/asymptomatic (20%), nausea (20%),
and abdominal pain (15%). The major sites of extrahepatic gastrointestinal spread were the
stomach (52%), peritoneum (38%), and omentum (19%). Average ﬁve-year survival from initial
diagnosis of ILC was 46%. Five-year survival from diagnosis of gastrointestinal metastasis
was 29%.
Conclusions: Approximately 1 in 20 patients diagnosed with ILC will have spread to the GI
tract, presenting 4 years after their initial primary diagnosis. Future research is needed in.11.006
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diagnosis of primary invasive lobular carcinoma of the
breast.
Demographic
Female (%) 100
Age at primary tumor diagnosis (years)
Mean 63
Median 61
Histology (%)1. Introduction
Breast Cancer is the most common malignancy in women.
Invasive lobular carcinoma (ILC) comprises 5–16% of all
breast cancer cases, making it the second most common
type of breast cancer [1–4]. While lung, brain, liver and
bone comprise the most common sites of metastatic spread,
it is not uncommon for breast cancer to metastasize to the
gastrointestinal tract [1,5]. Lobular carcinoma has a dis-
proportionately higher incidence of spread to the gastro-
intestinal (GI) system in comparison to other types of breast
cancer [1]. On a review of 12,001 patients with metastatic
breast cancer, ILC accounted for 58% of the GI metastasis
compared to 38% due to invasive ductal carcinomas (IDC),
although ILC comprised only 12% of the total breast cancers.
Post-mortem studies comparing metastatic ILC versus IDC
found a signiﬁcant propensity for metastatic spread of ILC to
the stomach, intestine and peritoneum compared to IDC
[2,6]. Still the literature on extrahepatic gastrointestinal
metastatic lobular carcinoma is comprised mostly of indivi-
dual case reports, small case series or autopsy series [1,5].
It is not uncommon for patients to ﬁrst present with
symptoms associated with their GI metastatic disease, like
early satiety, epigastric pain and weight loss, as their initial
presentation of their breast cancer rather than from mammo-
gram ﬁndings or physical exam of the breast [3]. Case reports
have even described a presumed gastric cancer, Linitis
Plastica, as the ﬁrst indication of ILC, which is an important
diagnostic distinction from a primary gastric cancer as the
treatment regimen is signiﬁcantly different [5,7].
The aim of this study is to describe quantitative demo-
graphic, epidemiological, medical, and treatment factors,
that may have an association with the risk of GI metastases.
Our case series of 21 patients is one of the larger case series
in the literature exclusively reporting on ILC with GI
metastasis. We also review the literature on clinical pre-
sentation, diagnosis, and outcomes in patients with ILC
metastasis to the extrahepatic gastrointestinal tract.Invasive lobular carcinoma 95
Mixed invasive lobular/ductal 5
Immunohistochemistry (%)
Estrogen receptor + 90
Progesterone receptor + 76
Human epidermal growth factor receptor 2+ 5
Staging (%)
1A 17
1B/2A 17
2B 22
3A 11
3B 6
3C 17
4 112. Patients and methods
After receiving ethics approval by the Research Ethics Ofﬁce
at the University of Alberta, a retrospective chart review
was conducted of all patients seen at the Cross Cancer
Institute in Edmonton, Alberta, Canada between 2005 and
2010, with a diagnosis of lobular breast cancer.
Only patients with a ﬁnal pathological tissue diagnosis of
invasive lobular breast cancer or mixed invasive lobular/
ductal and had extrahepatic gastrointestinal metastatic
disease were included. Exclusion criteria were any other
pathological breast cancer. Two independent reviewers
analyzed all records.The outcomes of interest included: age at diagnosis, site
of primary breast cancer, stage at initial presentation,
hormone receptor status, site of gastrointestinal metasta-
sis, time from diagnosis of breast primary to gastrointestinal
metastasis, time from gastrointestinal metastasis to death,
and treatment regimen for both primary and metastatic
disease.
3. Results
During the 5-year study period, 343 consecutive cases of
lobular breast cancer were reviewed, and 21(6%) were
found to have GI metastases and were included in this study.
3.1. Primary tumor patient demographics
Basic patient demographics were collected (Table 1). The
mean and median age at initial diagnosis of the primary
tumor were 63 (40–74) years and 61 years respectively.
Patient initial presentation varied; routine mammogram
(38%), palpable breast mass (38%), nipple inversion (14%),
fatigue (5%), and abdominal pain (5%). Cases were equally
distributed between both breasts, with 10/21 presentations
in the right breast, and 11/21 in the left breast. The site of
primary breast cancer was most commonly in the outer
Table 2 Demographic of patients with extrahepatic
gastrointestinal metastasis from primary invasive lobular
carcinoma of the breast.
Demographic
Age at metastatic diagnosis (years)
Mean 67
Median 68
Symptoms of GI disease (%)
Asymptomatic 20
Nausea 20
Abdominal Pain 15
Small Bowel obstruction 10
Dysphagia 5
GI bleed 5
Location of GI disease (%)
*6 patients had multiple site involvement
Stomach 52
Peritoneum 38
Omentum 19
Esophagus 10
Duodenum 5
Jejunum 5
Transverse colon 5
Pancreas 5
39Case series of 21 patientsupper quadrant; 40% for the right breast, and 54.5% for the
left breast.
Stage at presentation of the breast primary was: Stage
1A=17%, Stage 1B/2A=17%, Stage 2B=22%, Stage 3A=11%,
Stage 3B=6%, Stage 3C=17%, and Stage 4=11%. Receptor
status of the primary breast cancer was as follows: Human
epidermal growth factor receptor 2 (HER2) was positive in
5.3%, Progesterone receptor (PR) was positive in=76.2%,
and Estrogen receptor (ER) was positive 90.5%.
Five-year survival from initial diagnosis of lobular breast
cancer was 46% (Figure 1).
3.2. Treatment of primary tumor
Treatment at the time of diagnosis reﬂected the standard
of practice for breast cancer with 17 of the 21 (81%) primary
tumors being treated surgically; 8-mastectomy with axillary
node dissection, 4- lumpectomy with axillary node dis-
section, 2- lumpectomy with sentinel node biopsy, 2-
mastectomy with sentinel node biopsy, and 1-mastectomy.
13 patients (62%) received adjuvant hormonal therapy,
8 patients (38%) received adjuvant chemotherapy, 6 patients
(29%) received adjuvant radiotherapy and 1 patient refused
all treatment (5%).
3.3. Gastrointestinal metastatic disease
demographics
The mean age at time of diagnosis of metastatic disease was
67 years (Table 2). The mean interval from primary diag-
nosis to the GI metastatic presentation was 4 years. The
main initial patient presentations included; Asymptomatic
(20%), nausea (20%), abdominal pain (15%), small bowel
obstruction (10%), dysphagia (5%), and GI bleed (5%). Sites
of gastrointestinal spread included; Stomach (52%), perito-
neum (38%), omentum (19%), esophagus (10%), duodenum
(5%), jejunum (5%), transverse colon (5%), and pancreas
(5%). Six patients had multiple GI sites of involvement.
Palliative treatment, including surgery, chemotherapy
and radiation for metastatic disease was delivered in 17/
21 (80%) patients. Five-year survival from diagnosis of
gastrointestinal metastasis was 29% (Figure 2). While there
was no statistical difference between survival time in the0 5
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Figure 1 Kaplan Meier curve of overall survival of patients fromtreatment versus non treatment group, there is a suggestive
trend that treatment improves mean survival (10.8 months
versus 1.4 months). Due to the limited number of patients in
the no palliative treatment group, the survival analysis was
incomplete and did not reach signiﬁcance (Figure 3). Pallia-
tive surgery (n=2) versus no surgery (n=19) was also found
to not statistically improve survival outcomes, however
results are limited due to the small numbers in the
palliative surgery group (Figure 4).
Location of GI metastases was also analyzed. Patients
with metastatic disease involving the stomach (39%) and
omentum (40%) have improved 5-year survivals compared to
other sites (Figure 5).10 15 20
ears
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Figure 2 Kaplan Meier curve of overall survival of patients from diagnosis of extrahepatic gastrointestinal tract metastasis from
invasive lobular carcinoma of the breast.
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Figure 3 Overall survival beneﬁt of combined palliative treatment versus no treatment upon initial diagnosis of extrahepatic
gastrointestinal metastasis from invasive lobular breast cancer.
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Figure 4 Overall survival beneﬁt of palliative surgery versus no palliative surgery upon initial diagnosis of extrahepatic
gastrointestinal metastasis from invasive lobular breast cancer.
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Figure 5 Overall survival beneﬁt by extrahepatic gastrointestinal metastatic location from invasive lobular breast cancer.
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4.1. Invasive lobular carcinoma: a distinct entity
Invasive lobular carcinoma is a distinct tumor biology
subgroup of breast cancer, a histologically heterogeneous
disease [8]. Compared often to IDC, it has signiﬁcantly
different pathologic behavior that has marked clinical and
treatment consequences. ILC is characterized by a unique
growth pattern that displays an increased frequency for
contralateral breast involvement and is often multifocal and
multicentric [4,9]. Clinically, there is often a delay in
diagnosis. The primary tumor is often missed on breast
examination and screening mammogram, as it is less
demarcated on physical examination and has more subtle
mammographic features. For treatment, it is more difﬁcult
to achieve negative surgical margins in ILC tumors and an
associated increased local recurrence rate has been
described although this is debated in the literature [4,10].
It is therefore not surprising that the pattern of metastatic
spread is also unique, as ILC has a disproportionate ten-
dency for spread to the gastrointestinal tract [2,4]. There-
fore it is important to treat ILC as a distinct pathologic
entity compared to the ductal variant of breast cancer.
Our study reported a GI metastasis rate of 6% of patients
with ILC, which is within the 4–18% range quoted in the
literature [11]. The explanation behind the tropism of ILC
for the gastrointestinal tract remains to be clearly elicited,
but e-cadherins and the unique microenvironment of the GI
tract have been implicated. E-Cadherins are epithelial
speciﬁc cell-to-cell adhesion molecules that are responsible
for the maintenance of differentiation and prevention of
invasion. In normal glands, these molecules are well
expressed at the borders of epithelial cells and the loss of
these molecules have been implicated in lobular breast
carcinomas [12]. Studies looking at E-Cadherin expression
found that ILCs, in contrast to IDCs, stained negative for E-
Cadherins [12,13]. Therefore, ILCs form irregularly bor-
dered tumors with diffuse inﬁltration, are more invasive
and dedifferentiated, contrary to IDCs, which form cohesive
tumor groups [14]. While this does not explain why ILC
spreads speciﬁcally to the GI system, but it conﬁrms the factthat it has a distinct method of cellular invasion. Other
genes involved in lipid/fatty acid metabolism, immune
defense, stress responses, electron transport and nucleo-
some assembly have also have been implicated in the
dissimilar metastatic dissemination between the groups
[15]. Other theories on the predilection for the GI tract
postulate that potentially the unique microenvironment of
the gastrointestinal tract allows for proliferation of the
tumor cell by providing the necessary building blocks for
survival or the morphology of tumor cell shape might favor
being trapped in the microanatomy of the GI tract [8].
4.2. Diagnostic uncertainty
Patients presenting with GI metastasis can be challenging
diagnostically. Symptoms range widely from patients being
relatively asymptomatic to complaining of vague, non
speciﬁc GI symptoms of nausea, abdominal pain, and
dysphagia to more alarming symptoms of bowel obstruction
and GI bleed. Clinicians need to maintain a high index of
suspicion in patients with a history of breast cancer
presenting with gastrointestinal complaints,, regardless of
how remote the breast cancer. Our study reported a 4 year
mean interval time from diagnosis of primary breast cancer
to the development of GI metastasis, but there are litera-
ture case reports published about patient presentations
with GI metastasis as long as 30 years later [11]. The disease
free interval can be so markedly prolonged that case reports
have commented that the patient will often forget to even
report their history of breast cancer on the initial surgical
consult [5,16].
To make a challenging clinical situation even more
difﬁcult, lobular breast cancer metastases can mimic sev-
eral forms of primary gastric cancer: diffuse gastric inﬁltra-
tion can appear similar to linitis plastica type inﬁltration
and localized inﬁltration can be confused with small polyps
that can appear like a gastrointestinal stromal tumor (GIST)
[17]. Comparisons using immunohistochemistry, including
estrogen/progesterone receptor status, gross cystic disease
ﬂuid protein (GCDFP) and cytokeratin expression, should be
performed on/between the primary breast cancer (if possi-
ble) and the gastrointestinal specimen in all patients with a
N. Switzer et al.42history of previous breast cancer with a new diagnosis of a
GI neoplasm [16]. Unlike gastric cancers, metastatic lobular
cancers show strong estrogen receptor positivity (72%),
moderate progesterone positivity (33%), GCDFP reactivity
(78%), and cytokeratin 5 and 6 reactivity (61%). Another
confounding factor is that there are reports of lobular
breast cancers containing signet rings cells, which could
confuse the pathologist in incorrectly diagnosing a gastric
primary [18].4.3. Survival comparisons
It appears that there could be a survival beneﬁt with the
addition of palliative intervention upon the presentation of
metastatic gastrointestinal disease. However, due to this
study's small sample size, signiﬁcant conclusions are lim-
ited. Palliative therapy for metastatic breast cancer is
supported by the literature and is generally associated with
a survival beneﬁt [19–21]. Localization of extrahepatic GI
metastasis to the stomach and omentum are observed to be
associated with more favorable outcomes, although not
statistically signiﬁcant. This could be due to the earlier
presentation of these patients' symptoms with more prox-
imal GI obstruction.
Five-year survival from diagnosis of ILC gastrointestinal
metastasis was 29%. This is similar to the reported 5-year
survival rate of 25% reported in 2013 by the National Cancer
Institute for metastatic breast cancer of all ages [22].
Reported survival rates from metastatic breast cancer are
improving in the literature with the advent of newer
chemotherapy and targeted therapeutic agents, advances
in imaging technology and improved understanding of new
cancer pathways [23]. Compared to IDC, ILC has more
favorable histopathologic markers, increased ER receptor
positivity (76% versus 59.5%), low nuclear grade and
reduced HER-2 positivity [9,10]. HER-2 is associated with a
more aggressive form of breast cancer with decreased
overall survival, therefore, intuitively lower expression of
this growth factor receptor gene should translate with
survival beneﬁts but this is debated [9,10,24]. Studies have
shown mixed evidence that ILC is associated with a similar
[25], worse [10,26] or better [8,27] prognosis compared
to IDC.4.4. Treatment of ILC
Interestingly, in our data set, mastectomy was used in 11 of
21 patients, while breast-conserving therapy was only
performed in 6 of 21 patients. This likely speaks to the
difﬁculty in establishing tumor margins more than the
surgeon worrying about the risk of local recurrence, as this
point is debated in the literature. A mini review of the
literature in 2008 found 7 studies that reported on 5-year
local recurrence rates comparing ILC and IDC, and found
mixed results [10]. However one study found that ILC
treated by lumpectomy is 2 times more likely to be intra-
operatively converted to a mastectomy [28].
Palliative systemic hormone therapy is the primary treat-
ment modality of patients with progression of disease to
other organs including the GI tract [29]. Surgery is usuallyonly reserved for the complications of disease, including
obstruction, bleeding and perforation [29].
5. Conclusions
Approximately 1 in 20 patients diagnosed with a primary
breast cancer of lobular histology will have metastatic
spread to the GI tract, presenting approximately 4 years
after their initial primary diagnosis. The most common
presentation of metastatic disease is nausea and abdominal
pain, with the most common site of spread being the
stomach. There remains a paucity of data in the literature
and our project is one of the ﬁrst to further characterize
these patients. Future research is needed in developing
treatment regimens for these patients, as the 5-year
survival is only approximately 1 in 4.
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